References
1. Monstad I, Hovde O, Solberg IC, et al. Clinical course and prognosis in ulcerative colitis: results from population-based and observational studies. Annals of gastroenterology : quarterly publication of the Hellenic Society of Gastroenterology. 2014;27(2):95-104.
2. Jess T, Riis L, Vind I, et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflammatory bowel diseases. 2007;13(4):481-9.
3. Manosa M, Domenech E. [Mesalazine old and new]. Gastroenterologia y hepatologia. 2011;34 Suppl 3:25-9.
4. Grinspan A, Kornbluth A. Positioning Therapy for Ulcerative Colitis. Current gastroenterology reports. 2015;17(8):29.
5. Chaparro M, Gisbert JP. Maintenance therapy options for ulcerative colitis. Expert Opin Pharmacother. 2016:1-11.
6. Wang Y, Parker CE, Bhanji T, et al. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2016;4:CD000543.
7. Desreumaux P, Ghosh S. Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence. Alimentary pharmacology & therapeutics. 2006;24 Suppl 1:2-9.
8. Bohm SK, Kruis W. Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis. Clinical and experimental gastroenterology. 2014;7:369-83.
9. Gordon GL, Zakko S, Murthy U, et al. Once-daily Mesalamine Formulation for Maintenance of Remission in Ulcerative Colitis: A Randomized, Placebo-controlled Clinical Trial. Journal of clinical gastroenterology. 2015.
10. Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. Journal of Crohn's & colitis. 2012;6(10):991-1030.
11. Lennard-Jones JE. Classification of inflammatory bowel disease. Scandinavian journal of gastroenterology Supplement. 1989;170:2-6; discussion 16-9.
12. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Canadian journal of gastroenterology = Journal canadien de gastroenterologie. 2005;19 Suppl A:5A-36A.
13. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. The New England journal of medicine. 1987;317(26):1625-9.
14. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Medical care. 1986;24(1):67-74.
15. Pica R, Cassieri C, Cocco A, et al. A randomized trial comparing 4.8 vs. 2.4 g/day of oral mesalazine for maintenance of remission in ulcerative colitis. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2015;47(11):933-7.
16. Fockens P, Mulder CJ, Tytgat GN, et al. Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group. European journal of gastroenterology & hepatology. 1995;7(11):1025-30.
17. Paoluzi OA, Iacopini F, Pica R, et al. Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study. Alimentary pharmacology & therapeutics. 2005;21(9):1111-9.
18. Lichtenstein GR, Gordon GL, Zakko S, et al. Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis - a 6-month placebo-controlled trial. Alimentary pharmacology & therapeutics. 2010;32(8):990-9.
19. Li W, Zhang ZM, Jiang XL. Once daily versus multiple daily mesalamine therapy for mild to moderate ulcerative colitis: a meta-analysis. Colorectal Dis. 2016.
20. Hanauer SB, Sandborn WJ, Dallaire C, et al. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. Canadian journal of gastroenterology = Journal canadien de gastroenterologie. 2007;21(12):827-34.
21. Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol. 2005;100(11):2478-85.
22. Lichtenstein GR, Ramsey D, Rubin DT. Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing--ASCEND I and II combined analysis. Alimentary pharmacology & therapeutics. 2011;33(6):672-8.
23. Takeshima F, Matsumura M, Makiyama K, et al. Efficacy of long-term 4.0 g/day mesalazine (Pentasa) for maintenance therapy in ulcerative colitis. Med Sci Monit. 2014;20:1314-8.
24. Rubin DT, Bradette M, Gabalec L, et al. Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial. Journal of Crohn's & colitis. 2016.
25. Klotz U, Maier K, Fischer C, et al. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. The New England journal of medicine. 1980;303(26):1499-502.
26. Feagan BG, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012;10:CD000543.
27. Loftus EV, Jr., Kane SV, Bjorkman D. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Alimentary pharmacology & therapeutics. 2004;19(2):179-89.
28. Suzuki Y, Iida M, Ito H, et al. Efficacy and safety of two pH-dependent-release mesalamine doses in moderately active ulcerative colitis: a multicenter, randomized, double-blind, parallel-group study. Intest Res. 2016;14(1):50-9.
29. Ford AC, Khan KJ, Sandborn WJ, et al. Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(12):2070-7; quiz 8.
30. Zakko SF, Gordon GL, Murthy U, et al. Once-daily mesalamine granules for maintaining remission of ulcerative colitis: pooled analysis of efficacy, safety, and prognostic factors. Postgraduate medicine. 2016.
31. Van Staa TP, Travis S, Leufkens HG, et al. 5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study. Gastroenterology. 2004;126(7):1733-9.
32. Gisbert JP, Gonzalez-Lama Y, Mate J. 5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review. Inflammatory bowel diseases. 2007;13(5):629-38.
33. Bermejo F, Lopez-San Roman A, Algaba A, et al. Factors that modify therapy adherence in patients with inflammatory bowel disease. Journal of Crohn's & colitis. 2010;4(4):422-6.
34. Coenen S, Weyts E, Ballet V, et al. Identifying predictors of low adherence in patients with inflammatory bowel disease. European journal of gastroenterology & hepatology. 2016;28(5):503-7.
35. Haase J, Farris KB, Dorsch MP. Mobile Applications to Improve Medication Adherence. Telemed J E Health. 2016.
36. Lopez-Sanroman A, Bermejo F. Review article: how to control and improve adherence to therapy in inflammatory bowel disease. Alimentary pharmacology & therapeutics. 2006;24 Suppl 3:45-9.
37. Robinson A. Review article: improving adherence to medication in patients with inflammatory bowel disease. Alimentary pharmacology & therapeutics. 2008;27 Suppl 1:9-14.